Resmed Champions Sleep Health as The Official Sleep Partner of The Qatar Airways British & Irish Lions Tour to Australia 2025
SAN DIEGO and LONDON and DUBLIN and SYDNEY, May 15, 2025 (GLOBE NEWSWIRE) — Resmed (NYSE: RMD, ASX: RMD), the leading health technology company focused on sleep, breathing, and care delivered in the home, has been named the Official Sleep Partner of the Qatar Airways British & Irish Lions Tour to Australia.
The Tour brings rugby fans' dreams to life over a six-week period. For the first time in 12 years, The Lions squad, alongside an estimated 40,000 fans, will battle it out with the Wallabies, Super Rugby Pacific teams, and exhibition sides in six cities across Australia.
As the Official Sleep Partner, Resmed will launch 'Tackle Your Sleep,' a digital and content focused campaign featuring legendary rugby players. The campaign takes a light-hearted look at serious sleep health issues affecting players and the fans in Australia, the UK, and Ireland, with the rugby legends sharing advice and tools to support better sleep. The campaign aims to raise awareness about the importance of quality sleep for the rugby players and fans, as the third pillar of health, alongside exercise and diet1.
Poor sleep can take a serious toll on mental health, physical health2, relationships3, and daily performance4. For athletes, it can impair optimal training, motivation, physical performance, and increase the risk of fatigue-related injuries3. A study of 175 rugby and cricket players found that half were classified as poor sleepers, with many reporting significant daytime fatigue5 — highlighting how sleep hygiene and recovery routines can offer a real competitive edge.
Despite these known negative effects,
Resmed's 2025 Global Sleep Survey found
that one in four people globally are choosing to live with poor sleep6.
Katrin Pucknat, Chief Marketing Officer of Resmed, said: 'Poor sleep affects every aspect of our lives, but the good news is there are steps we can take to improve our sleep health.
'As the Official Sleep Partner of the tour, we're excited to raise awareness about the powerful connection between sleep and athletic performance and inspire fans to think about the role that sleep plays in their own lives, while having some fun along the way.'
Ben Calveley, CEO of The British & Irish Lions said: 'The Lions are always seeking new ways to support our players and management team and sleep is a vital component of performance.
'Resmed adds another dimension to our acclimatisation and recovery strategies, ensuring the squad is primed to perform for the duration of the Tour. They will also be sharing insights to help travelling supporters stay well rested and in full voice for each fixture.'
Rugby Australia CEO, Phil Waugh said: 'Resmed is a leader in their field and we're incredibly pleased to welcome them as an official partner for this year's British & Irish Lions Tour.
'Quality sleep is certainly important for our players to perform at their best but there's no doubt good sleep is just as vital for all those celebrating and connecting throughout the Tour across Australia.'
The British & Irish Lions will play 10 matches in total, with three Test matches against the Wallabies in Brisbane, Melbourne, and Sydney.
About The British & Irish Lions
The British & Irish Lions is an iconic sporting brand in the world of rugby. Every four years, the Lions Men – the best of the best selected from England, Ireland, Scotland and Wales – travel to the southern hemisphere to take on Australia, New Zealand, or South Africa on landmark tours.
The British & Irish Lions has announced the initial details of a historic inaugural Lions Women's Tour with the best women's players from England, Ireland, Scotland, and Wales traveling to New Zealand to play the current world champions in 2027. The British & Irish Lions will continue to collaborate with all key stakeholders, including its constituent Unions, World Rugby, and the various leagues to finalise full Tour details.
The Lions is the pinnacle of players' careers, a once in a lifetime experience for fans and leaves an enduring legacy wherever the team visits. The Lions foundations are strong, built upon 130 years of history and tradition with tours taking place regularly since 1888.
About Resmed
Resmed (NYSE: RMD, ASX: RMD) creates life-changing health technologies that people love. We're relentlessly committed to pioneering innovative technology to empower millions of people in 140 countries to live happier, healthier lives. Our AI-powered digital health solutions, cloud-connected devices, and intelligent software make home healthcare more personalized, accessible, and effective. Ultimately, Resmed envisions a world where every person can achieve their full potential through better sleep and breathing, with care delivered in their own home. Learn more about how we're redefining sleep health at
resmed.com
and follow @Resmed.
For Media:
Cassie-Anne Low, Resmed
cassie-anne.low@resmed.com.sg
news@Resmed.com
For Investors:
Mike Ott, Resmed
Investorrelations@resmed.com
The 2025 British and Irish Lions Tour of Australia
1 Stott D, Forde D, Sharma C, et al. Interactions with Nature, Good for the Mind and Body: A Narrative Review.
Int J Environ Res Public Health
. 2024;21(3):329. Published 2024 Mar 12. doi:10.3390/ijerph21030329he
2 Lloyd-jones et al, Life's Essential 8: Updating and Enhancing the American Heart Association's Construct of Cardiovascular Health: A Presidential Advisory From the American Heart Association, Circulation 2022
3 Gordon AM, Chen S. The role of sleep in interpersonal conflict: Do sleepless nights mean worse fights? Social Psychological and Personality Science. 2014;5(2):168–175
4 Perry GS, Patil SP, Presley-Cantrell LR. Raising awareness of sleep as a healthy behavior. Prev Chronic Dis. 2013
5 Swinbourne R, Gill N, Vaile J, Smart D. Prevalence of poor sleep quality, sleepiness and obstructive sleep apnoea risk factors in athletes. Eur J Sport Sci. 2016 Oct;16(7):850-8. doi: 10.1080/17461391.2015.1120781. Epub 2015 Dec 23. PMID: 26697921.
6 Resmed's 2025 Global Sleep Survey
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
an hour ago
- Yahoo
Teva Announces Pricing and Early Acceptance Results of its Debt Tender Offer
TEL AVIV, Israel, June 03, 2025 (GLOBE NEWSWIRE) -- Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) ('Teva') announced today the pricing and early acceptance results of its previously announced tender offers (the 'Offers') to purchase for cash the outstanding notes issued by finance subsidiaries of Teva and guaranteed by Teva of the series described in the table below (the 'Notes') upon the terms of, and subject to the conditions as set out in, the Offer to Purchase, dated May 19, 2025 (the 'Offer to Purchase'). Capitalized terms used in this announcement but not otherwise defined shall have the meanings given to them in the Offer to Purchase. Upon the terms and subject to the conditions set forth in the Offer to Purchase, the early acceptance results and the Total Consideration for each applicable series of the Notes are set forth in the following table: Dollars or Euros per $1,000 or €1,000, as applicable, principal amount Capped Tender Offers Title of Notes Issuer CUSIP / ISIN / Common Code Principal Amount Tendered(2) Pool Tender Caps (purchase price)(1)(2) Acceptance Priority Level(3) Principal Amount to be Accepted Proration Factor Principal Amount Outstanding after Early Settlement Date Reference Security or Interpolated Mid-Swap Rate Fixed Spread (basis points)(7) Tender Offer Consideration (4) Early Tender Premium Total Consideration (4)(5) Pool 1 Tender Offers 3.150% Senior Notes due 2026 Teva Pharmaceutical Finance Netherlands III B.V. 88167AAE1 / US88167AAE10 (Registered) $2,602,331,000 $1,550,000,000 1 $1,579,185,000 60.74999% $1,798,459,000 N/A N/A $931.50 $50.00 $981.50 Pool 2 Tender Offers 4.750% Sustainability-Linked Senior Notes due 2027 Teva Pharmaceutical Finance Netherlands III B.V. 88167AAP6 / US88167AAP66 (Registered) $781,072,000 $350,000,000 (equivalent) 2 $350,877,000 39.4586% $649,123,000 N/A N/A $947.50 $50.00 $997.50 3.750% Sustainability-Linked Senior Notes due 2027 Teva Pharmaceutical Finance Netherlands II B.V. XS2406607098 / 240660709 (Registered) €532,083,000 3 €0 N/A €1,100,000,000 N/A N/A €963.50 €50.00 €1,013.50 Pool 3 Tender Offers 7.875% Sustainability-Linked Senior Notes due 2029 Teva Pharmaceutical Finance Netherlands III B.V. 88167AAS0 / US88167AAS06 (Registered) $202,316,000 $400,000,000(equivalent) 4 $202,316,000 N/A $397,684,000 4.016% + 135 $1,039.78 (6) $50.00 $1,089.78 (7) 7.375% Sustainability-Linked Senior Notes due 2029 Teva Pharmaceutical Finance Netherlands II B.V. XS2592804434 / 259280443 (Registered) €349,888,000 5 €137,418,000 36.663% €662,582,000 2.100% + 150 €1,091.64 (6) €50.00 €1,141.64 (7) 8.125% Sustainability-Linked Senior Notes due 2031 Teva Pharmaceutical Finance Netherlands III B.V. 88167AAR2 / US88167AAR23 (Registered) $116,975,000 6 $0 N/A $500,000,000 4.016% + 155 $1,079.49 (6) $50.00 $1,129.49 (7) (1) The tender cap for the Pool 1 Notes of $1,550,000,000 (the 'Pool 1 Tender Cap') represents the maximum aggregate purchase price in respect of Pool 1 Notes that will be purchased in the Pool 1 Tender Offers. The tender cap for the Pool 2 Notes of $350,000,000 (the 'Pool 2 Tender Cap') represents the maximum aggregate purchase price in respect of Pool 2 Notes that will be purchased in the Pool 2 Tender Offers. The tender cap for the Pool 3 Notes of $400,000,000 (the 'Pool 3 Tender Cap' and, together with the Pool 1 Tender Cap and the Pool 2 Tender Cap, the 'Pool Tender Caps') represents the maximum aggregate purchase price in respect of Pool 3 Notes that will be purchased in the Pool 3 Tender Offers. The Pool Tender Caps can be increased or decreased at Teva's sole discretion.(2) In order to determine whether the Total Maximum Amount and Pool Tender Caps have been reached, an exchange rate of $1.1443 = €1.00 has been used, as determined at 10:30 a.m. Eastern Time on the date of the Early Tender Time.(3) Subject to the Total Maximum Amount, the Pool Tender Caps and proration, the principal amount of each series of Notes that is purchased in each of the Offers will be determined in accordance with the applicable acceptance priority level (in numerical priority order) specified in this column.(4) Excludes accrued and unpaid interest, which also will be paid. The Total Consideration in respect of the Pool 3 Notes was calculated at 10:30 a.m., New York City time, on June 3, 2025 (the 'Price Determination Time') in accordance with standard market practice, as described in the Offer to Purchase.(5) Already includes the Early Tender Premium.(6) The Tender Offer Consideration in respect of the Notes of each relevant series equals the applicable Total Consideration minus the applicable Early Tender Premium.(7) The Total Consideration in respect of the Pool 3 Notes of each relevant series was calculated from the applicable Reference Yield and the applicable Fixed Spread and which, when calculated in such manner, already includes the applicable Early Tender Premium. The applicable Total Consideration was calculated with reference to the First Par Call Date, as detailed in the Offer to Purchase.(8) Pricing Source: BGN. Early participation results of the Offers were announced on June 3, 2025. The amounts of each series of Notes to be accepted are shown in the table. The Notes tendered with Acceptance Priority Level 4 shall be accepted in full without proration. The Notes with Acceptance Priority Levels 1, 2 and 5 shall be accepted subject to a proration factor of approximately 60.74999%, 39.4586% and 36.663%, respectively. In accordance with the applicable Acceptance Priority Levels, no Notes with Acceptance Priority Levels 3 and 6 will be accepted by Teva pursuant to the Offers. Subject to the terms and conditions of the Offers, Holders that validly tendered and did not validly withdraw their Notes at or prior to the Early Tender Time and whose Notes are accepted for purchase by Teva will be eligible to receive the applicable Total Consideration, which already includes the Early Tender Premium, together with an amount equal to the Accrued Interest. Teva expects the Initial Settlement Date to occur on June 5, 2025, the third business day after the Early Tender Time. The consummation of the Offers and Teva's obligation to accept and pay for the Notes validly tendered (and not validly withdrawn) pursuant to the Offers are subject to the satisfaction or waiver of certain conditions described in the Offer to Purchase and subject to the applicable Pool Tender Cap. Teva reserves the right, subject to applicable law, to amend or waive any and all conditions to the Offers. The Offers will expire at 5:00 p.m., Eastern Time, on Tuesday, June 17, 2025, unless extended or earlier terminated (as it may be extended or earlier terminated, the 'Expiration Time'). However, as Teva intends, subject to the terms and conditions of the Offers, to accept for purchase the Total Maximum Amount on the Initial Settlement Date, further tenders of Notes prior to the Expiration Time will not be accepted for purchase. The settlement of Teva's $2.3 billion (equivalent) senior notes offering on May 28, 2025 satisfied the financing condition to the Offer. The purchase price for the Dollar Notes and the Euro Notes will be paid in U.S. Dollars and Euros, respectively. BNP PARIBAS, HSBC Bank plc, Intesa Sanpaolo S.p.A., J.P. Morgan Securities plc and Merrill Lynch International (or their respective affiliates) are acting as the Dealer Managers for the Offers. The information and tender agent (the 'Information and Tender Agent') for the Offers is D.F. King. Copies of the Offer to Purchase are available by contacting the Information and Tender Agent at (800) 967-5068 (toll-free), (212) 269-5550 (collect) or +44 20-7920-9700 (UK) or by email at teva@ All documentation relating to the offer, together with any updates, will be available via the Offer Website: Questions regarding the Offers should be directed to BNP PARIBAS, at +33 1 55 77 78 94 (Europe), +1 (888) 210 4358 (U.S. Toll Free), +1 (212) 841 3059 (U.S.) or by email at to HSBC Bank plc, at +44 20 7992 6237 (Europe), +1 (888) HSBC-4LM (U.S. Toll Free), +1 (212) 525-5552 (Collect) or by email at LM_EMEA@ to Intesa Sanpaolo S.p.A., at +39 02 7261 6502 or by email at to J.P. Morgan Securities LLC at +1 (866) 834-4666 (U.S. toll free), +1 (212) 834-4818 (Collect), to J.P. Morgan Securities plc at +44 207 134 2468 (Europe) or by email at liability_management_emea@ and to Merrill Lynch International at +44 207 996 5420 (Europe), +1 (888) 292-0070 (U.S. Toll Free) or by email at This announcement shall not constitute an offer to sell, a solicitation to buy or an offer to purchase or sell any Notes. The Offers are being made only pursuant to the Offer to Purchase and only in such jurisdictions as is permitted under applicable law. About Teva Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) is a different kind of global biopharmaceutical leader, one that operates across the full spectrum of innovation to reliably deliver medicines to patients worldwide. For over 120 years, Teva's commitment to bettering health has never wavered. Today, the company's global network of capabilities enables its 37,000 employees across 57 markets to advance health by developing medicines for the future while championing the production of generics and biologics. We are dedicated to addressing patients' needs, now and in the future. Moving forward together with science that treats, inspired by the people we serve. Cautionary Note Regarding Forward-Looking Statements This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, which are based on management's current beliefs and expectations and are subject to substantial risks and uncertainties, both known and unknown, that could cause our future results, performance or achievements to differ significantly from that expressed or implied by such forward-looking statements. Important factors that could cause or contribute to such differences include risks relating to: settlement of the tender offers for certain outstanding notes; our significant indebtedness, which may limit our ability to incur additional indebtedness, engage in additional transactions or make new investments, and may result in a further downgrade of our credit ratings; our inability to raise debt or borrow funds in amounts or on terms that are favorable to us; and other factors discussed in our Quarterly Report on Form 10-Q for the first quarter of 2025, our Annual Report on Form 10-K for the year ended December 31, 2024, including the sections thereof captioned 'Risk Factors' and 'Forward Looking Statements,' and other filings with the SEC, which are available at Forward-looking statements speak only as of the date on which they are made, and we assume no obligation to update or revise any forward-looking statements or other information contained herein, whether as a result of new information, future events or otherwise. You are cautioned not to put undue reliance on these forward-looking statements. No assurance can be given that the transactions described herein will be consummated or as to the ultimate terms of any such transactions. Teva Media Inquiries:TevaCommunicationsNorthAmerica@ Teva Investor Relations InquiresTevaIR@ in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
an hour ago
- Yahoo
Ultragenyx to Participate at Goldman Sachs 46th Annual Global Healthcare Conference
NOVATO, Calif., June 03, 2025 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), a biopharmaceutical company focused on the development and commercialization of novel therapies for serious rare and ultra-rare genetic diseases, today announced that Emil Kakkis, M.D., Ph.D., the company's chief executive officer, will participate in a fireside at the Goldman Sachs 46th Annual Global Healthcare Conference on Tuesday, June 10, 2025, at 10:00 a.m. ET. The live and archived webcast of the panel will be accessible from the company's website at About Ultragenyx Pharmaceutical Inc. Ultragenyx is a biopharmaceutical company committed to bringing novel products to patients for the treatment of serious rare and ultra-rare genetic diseases. The company has built a diverse portfolio of approved therapies and product candidates aimed at addressing diseases with high unmet medical need and clear biology for treatment, for which there are typically no approved therapies treating the underlying disease. The company is led by a management team experienced in the development and commercialization of rare disease therapeutics. Ultragenyx's strategy is predicated upon time- and cost-efficient drug development, with the goal of delivering safe and effective therapies to patients with the utmost urgency. For more information on Ultragenyx, please visit the company's website at: Contacts – Ultragenyx Pharmaceutical, Higa ir@
Yahoo
an hour ago
- Yahoo
Elizabeth Day Tried Everything to Get Pregnant. After 12 Years, She Stopped — and Found Meaning in Failure (Exclusive)
After 12 years of trying to get pregnant, Elizabeth Day decided it was time to stop — and what she realized next was unexpected. The 46-year-old British podcaster and novelist, who hosts the podcast How to Fail with Elizabeth Day, says she always knew she wanted to have kids. Growing up in a heteronormative family with two sisters and two parents, Day believed she was going to be a mother from the very beginning. "I don't think I ever questioned the fact that I would have children," she tells PEOPLE. Never miss a story — sign up for to stay up-to-date on the best of what PEOPLE has to offer, from celebrity news to compelling human interest stories. Day, who grew up attending an all-girls school, explains that she went on birth control when she became sexually active and was on the pill for 14 years before she stopped taking it after getting married to her first husband. "I thought, because there is this idea that if you come off the pill, there's this sort of fertility boost sometimes and you can get pregnant at the drop of a hat," Day says. "And so I thought that might happen, but actually it didn't happen at all. And that's when I started exploring whether there was something awry." Day spent two years trying to get pregnant with her ex-husband before she decided to see a doctor, a time period which she calls a "very lonely experience." Ultimately, she was told she had "unexplained infertility." "[It's] a deeply unhelpful diagnosis because there's no explanation, so no one's quite sure how to treat it, so they just throw stuff at a wall and see what sticks," she explains. The doctors also told her she had a bicornuate uterus which, according to The Cleveland Clinic, is an irregularly shaped uterus that appears to be heart-shaped and can often cause complications with pregnancy. However, throughout all her meetings and appointments with "almost exclusively male clinicians," Day just kept feeling frustrated. She shares that she began to realize that women's medicine is "under-explored, underfunded and under-researched." "So very often when I asked for an explanation, I was told that I was the one who was failing," Day says. "So the language of infertility is very much the language of failure, which is partly why I'm so interested in exploring failure through my podcast is because of these experiences." "It puts the onus on women, and it is very often women who feel that — particularly if you are a kind of type A perfectionist, which I think I was — and you are used to putting in the work and hopefully getting the results, this is something that you cannot possibly control by being quote unquote, 'a good girl.' And I found that really difficult on top of all of the hormones." She was then advised to try in vitro fertilization (IVF), which she started during the beginning of 2014. After two rounds of IVF, Day was again unsuccessful in getting pregnant after transferring an embryo. "And again, there was no explanation for that. So I turned the sense of failure inwards, and it was actually talking to a friend of mine that really helped me kind of recategorize that experience," she explains. "And I told her I was failing to respond to the drugs, and she said, 'Maybe you're not failing to respond to the drugs. Maybe they're failing you.'" Describing that chat as a "lightbulb moment," Day says reframing the way she thought about failure changed how she saw the experience of fertility medicine. She took a break from IVF and ended up getting pregnant naturally, but had the first of three miscarriages at the end of the year in 2014. "2014 was a really intense year, partly because as anyone who has done fertility treatment will know, it's like having another job," Day explains. "There are so many scans that you have to go to. There's so many drugs that you have to take. There's so much measuring and prodding that happens and you are constantly living with this state of ambivalence and ambiguity because it might work, but it might not. And you need to carry both ideas." She explains that even getting something like a positive pregnancy test, which is often a very happy thing for couples, carries weight to it when you're going through miscarriages and fertility treatments. "There's this really difficult tension between all of your feelings because on the one side, you know you should feel uncomplicatedly ecstatic," Day says. "But on the other side, you know how fragile it can be. And if you've had a miscarriage, it robs you of any experience of a relaxed pregnancy." "Now that I've had three miscarriages, I also understand that it's a very nuanced type of grief because you are grieving an absence, but you are also grieving the dreams you had of a presence," she continues. "And that's a really hard thing to cope with." After a tough year, Day divorced from her first husband in 2015. She went on to freeze her eggs and unfortunately did not retrieve that many since she again was told she "failed to respond to drugs properly." When she was about to turn 40, Day met her now-husband on Hinge. She thought there wasn't much hope at getting pregnant since she was now older and her husband was 44, but she did end up getting pregnant naturally just after her 41st birthday. When that pregnancy also ended in miscarriage, Day says it showed herself and her partner how much they really wanted to have a baby. The two embarked on their own fertility journey, which ended with trying egg donation. Day explains that she felt like she was at an age where she would prefer to have a healthy egg that produces a viable embryo, rather than try using her own eggs. After a year of finding a donor and adjusting her lifestyle, she traveled to Los Angeles just after Christmas in 2022 for the embryo transfer. And it did not take. "Again, you are pitched into this devastating realization that there is no explanation that even when you do everything you are meant to do, sometimes it just doesn't happen," Day says. "And that was one of the lowest points of my life." "Looking back, that's over two years ago now, and I could never have imagined that I would be here, which is fully at peace with a life without biological children," she shares. "And the reason I am at peace with it, I had to confront some dark things. I had to ask myself some honest questions. But ultimately, it came down to the idea that maybe it's not my path in this lifetime to be a mother in the conventional sense." Day notes that she's lucky enough to have three step kids, two nieces and 13 godchildren. "I'm very blessed in that respect, and I'm very aware that there are so many different ways to show up in a parenting role in this world," she adds. She goes on to say that although the entire infertility journey is a very difficult one, she has learned something meaningful about herself, about love and about life. "It's my firm belief that actually going through the fertility struggles is an act of parenting," Day says. "That's what you're doing. You are parenting your child, you are living your life for your children, giving them existence," she continues. "And that's an extraordinary thing that you are doing, and you are so strong to be doing it." Day explains that while she was in the thick of trying to get pregnant, the thought of giving up was one she couldn't comprehend. "I thought [not having children] would mean my life wouldn't have meaning that I would be left behind and that I would feel something so fundamentally lacking," she shares. "I promise you that there is so much peace and fulfillment on the other side of it and so many opportunities to create meaning." "I think ultimately for me, part of my journey has been realizing how much I need to parent myself. And I think that's a struggle that many of us have," Day says "And so actually part of my parenting now is understanding what I need and that it's not a failure to meet those needs. And nor is it selfish. It's actually a really necessary part of being human." The podcaster goes on to explain that she's found meaning and a real sense of community by doing her podcast, which explores this topic of failure. "So I just want to say that to the person who is walking that path right now, there will be a way that you can find meaning again if it's not conventional parenting, and if it is and you do end up with a baby in your arms, I'm so so happy for you, and that is your path," Day says. "And I realize now that it's not mine." Read the original article on People
